Synapse - Geoffrey Ku

Results (235)

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers

Meeting Abstract

Park, D.; Yoon, C.; Thomas, N.; Ku, G. Y.; Janjigian, Y. Y.; Kelsen, D. P.; Ilson, D. H.; Goodman, K. A.; Tang, L. H.; Strong, V. E.; more...
Annals of Surgical Oncology (2014)

Fulltext@MSK | Save

FDG-PET scan after induction chemotherapy for esophageal squamous cell cancer (ESCC) to predict for outcomes after chemoradiation (chemoRT) and to guide salvage chemotherapy during RT

Meeting Abstract

Ku, G. Y.; Janjigian, Y. Y.; Kriplani, A.; Ong, L.; Rusch, V. W.; Bains, M. S.; Rizk, N. P.; Sarkaria, I. S.; Capanu, M.; Goodman, K. A.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer

Journal Article

Janjigian, Y. Y.; Ku, G. Y.; Campbell, J. C.; Shah, M. A.; Capanu, M.; Kelsen, D. P.; Ilson, D. H.
American Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma

Meeting Abstract

Ku, G. Y.; Janjigian, Y. Y.; Shah, M. A.; Herrera, J.; Tang, L. H.; Fuqua, L.; Capanu, M.; Ilson, D.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma

Meeting Abstract

Ku, G. Y.; Kelsen, D. P.; Strong, V. E.; Schöder, H.; Janjigian, Y. Y.; Shah, M. A.; Coit, D. G.; Brennan, M. F.; Capanu, M.; Ilson, D. H.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer